The first 2 years of the COVID-19 pandemic were mainly characterized by recurrent
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …

The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …

Emergent Coronaviridae viruses, such as SARS-CoV-1 in 2003, MERS-CoV in 2012, and
SARS-CoV-2 (CoV-2) in 2019, have caused millions of deaths. These viruses have added to …

Since December 2019, SARS-CoV-2 is ravaging the globe, currently accounting for over
660 million infected people and more than 6.6 million deaths. As convalescent plasma had …

Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19)
pandemic, serves as the basis for our study, which relies on the Food and Drug …

Synopsis Background The UK Medicines and Regulatory Healthcare Agency (MHRA) have
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …

Summary Objectives The SARS-CoV-2 pandemic and large-scale genomic surveillance
provided an exceptional opportunity to analyze mutations that appeared over three years in …